Search clinical trials for: Lemborexant

Total 33 results

Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Irregular Sleep-Wake Rhythm Disorder

United States, Japan, United Kingdom
Kurume University
Eisai Inc.; Mebix Inc

Completed

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia

Insomnia

Japan
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

Healthy Participants

Netherlands
Washington University School of Medicine

Recruiting

DORA and LP in Alzheimer's Disease Biomarkers

Alzheimer Disease

United States
Eisai Inc.

Completed

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Insomnia Disorder

United States
Nova Scotia Health Authority

Recruiting

Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

Insomnia | Dementia | Frontotemporal Dementia

Canada
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

Obstructive Sleep Apnea | Healthy Subjects

United States
Eisai Inc.

Completed

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

United States, Canada, Finland, Germany, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Spain
Eisai Inc.

Completed

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sleep Apnea, Obstructive | Respiration Disorders | Pulmonary Disease, Chronic Obstructive

United States
Chulalongkorn University

Recruiting

Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold (LOSALAT)

OSA

Thailand
Eisai Inc.
Purdue Pharma LP

Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Insomnia Disorders

Canada
Guangdong Provincial People's Hospital
Nanfang Hospital, Southern Medical University

Not yet recruiting

Patient-Reported Outcomes for Lemborexant in Chinese Participants With Insomnia (PROEM)

Insomnia

China
Centre Integre Universitaire de Sante et Services...

Recruiting

The Effects of Lemborexant on the Ability to Sleep During Daytime

Shift-Work Sleep Disorder

Canada
Brendan Lucey
Eisai Inc.

Withdrawn

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Alzheimer Disease

United States
Eisai Inc.

Completed

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (SUNRISE 1)

Insomnia

United States, Spain, United Kingdom, Italy, Germany, France, Canada
Baylor College of Medicine

Completed

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

Alcohol Use Disorder

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
University of California, San Francisco

Recruiting

Lemborexant Shift Work Treatment Study

Shift-Work Related Sleep Disturbance

United States
Eisai Co., Ltd.

Completed

A Study of Lemborexant in Chinese Participants With Insomnia Disorder

Sleep Initiation and Maintenance Disorders

Taiwan, China
Eisai Co., Ltd.

Recruiting

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Eisai Co., Ltd.

Completed

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

Healthy Volunteer

China
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
University of Manitoba
Duke University

Not yet recruiting

Lemborexant Treatment of Insomnia Linked to Epilepsy (L'ÉTOILE)

Epilepsy | Sleep
Stanford University
University of California, San Francisco

Recruiting

Lemborexant in Delayed Sleep Phase Syndrome

Delayed Sleep Phase Syndrome

United States
Eisai Co., Ltd.

Completed

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

Sleep Initiation and Maintenance Disorders

Japan
Eisai Inc.

Completed

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Healthy Volunteers

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study of Lemborexant-Alcohol Interaction in Healthy Subjects

Healthy Subjects

Canada
Eisai Inc.

Completed

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Insomnia

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Healthy Subjects

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Completed

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Drug Interaction | Analgesics, Opioid

United States
Salem Anaesthesia Pain Clinic

Recruiting

Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients

Chronic Pain | Chronic Insomnia

Canada
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia

3

Subscribe